Acute Repetitive Seizures

Neurology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Neurelis
NeurelisCA - San Diego
2 programs
1
1
NRL-1Phase 31 trial
NRL-1Phase 11 trial
Active Trials
NCT02724423Completed57Est. Sep 2019
NCT02721069Completed175Est. Jul 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NeurelisNRL-1
NeurelisNRL-1

Clinical Trials (2)

Total enrollment: 232 patients across 2 trials

NCT02721069NeurelisNRL-1

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

Start: Apr 2016Est. completion: Jul 2020175 patients
Phase 3Completed
NCT02724423NeurelisNRL-1

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

Start: Jun 2016Est. completion: Sep 201957 patients
Phase 1Completed

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)